The role of bile pigments in health and disease: Effects on cell signaling, cytotoxicity, and cytoprotection

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Kapitulnik, Jaime ^a   Maines, Mahin D ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE PIGMENT; BILIRUBIN; BILIVERDIN REDUCTASE; HEME; HEME OXYGENASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN DAMAGE; CARDIOVASCULAR DISEASE; CATABOLISM; CELL PROTECTION; CYTOTOXICITY; GILBERT DISEASE; HEART PROTECTION; HUMAN; HYPERBILIRUBINEMIA; NEUROTOXICITY; SIGNAL TRANSDUCTION;

EID: 84866157970     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00136     Document Type: Article

References (19)

1. Araujo, J. A., Zhang, M., and Yin, F. (2012). Heme oxygenase-1, oxidation, inflammation and atherosclerosis. Front. Pharmacol. 3:119. doi: 10.3389/fphar.2012.00119
2. Bock, K.W. (2011). Regulation of bilirubin clearance by ligand-activated transcription factors of the endo- and xenobiotic metabolism system. Front. Pharmacol. 2:82. doi: 10.3389/fphar.2011.00082
3. Brites, D. (2012). The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front. Pharmacol. 3:88. doi: 10.3389/ fphar.2012.00088
4. Dennery, P. A. (2012). Evaluating the beneficial and detrimental effects of bile pigments in early and later life. Front. Pharmacol. 3:115. doi: 10.3389/fphar.2012.00115
5. Gazzin, S., Strazielle, N., Tiribelli, C., and Ghersi-Egea, J. F. (2012). Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy. Front. Pharmacol. 3:89. doi: 10.3389/fphar.2012.00089
6. Gibbs, P. E., Tudor, C., and Maines, M. D. (2012). Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front. Pharmacol. 3:31. doi: 10.3389/fphar.2012.00031
7. Jansen, T., and Daiber, A. (2012). Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase? Front. Pharmacol. 3:30. doi: 10.3389/ fphar.2012.00030
8. Kapitulnik, J., Benaim, C., and Sasson, S. (2012). Endothelial cells derived from the blood-brain barrier and islets of Langerhans differ in their response to the effects of bilirubin on oxidative stress under hyperglycemic conditions. Front. Pharmacol. 3:131. doi: 10.3389/fphar.2012.00131
9. Kim, S. Y., and Park, S. C. (2012). Physiological antioxidative network of the bilirubin system in aging and age-related diseases. Front. Pharmacol. 3:45. doi: 10.3389/ fphar.2012.00045
10. Larsen, R., Gouveia, Z., Soares, M. P., and Gozzelino, R. (2012). Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front. Pharmacol. 3:77. doi: 10.3389/fphar.2012.00077
11. Lundvig, D. M., Immenschuh, S., and Wagener, F. A. (2012). Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly? Front. Pharmacol. 3:81. doi: 10.3389/fphar.2012.00081
12. Peyton, K. J., Shebib, A. R., Azam, M. A., Liu, X. M., Tulis, D. A., and Durante, W. (2012). Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front. Pharmacol. 3:48. doi: 10.3389/fphar.2012.00048
13. Ryter, S. W. (2012). Bile pigments in pulmonary and vascular disease. Front. Pharmacol. 3:39. doi: 10.3389/fphar.2012.00039
14. Santangelo, R., Mancuso, C., Marchetti, S., Di Stasio, E., Pani, G., and Fadda, G. (2012). Bilirubin: an endogenous molecule with antiviral activity in vitro. Front. Pharmacol. 3:36. doi: 10.3389/fphar.2012.00036
15. Schmidt, W. N., Mathahs, M. M., and Zhu, Z. (2012). Heme and HO-1 inhibition of HCV, HBV, and HIV. Front. Pharmacol. 3:129. doi: 10.3389/ fphar.2012.00129
16. Schulz, S., Wong, R.J., Vreman, H.J., and Stevenson, D.K. (2012). Metalloporphyrins - an update. Front. Pharmacol. 3:68. doi: 10.3389/fphar.2012.00068
17. Stec, D. E., Hosick, P. A., and Granger, J. P. (2012). Bilirubin, renal hemodynamics, and blood pressure. Front. Pharmacol. 3:18. doi: 10.3389/fphar.2012.00018
18. Vitek, L. (2012). The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front. Pharmacol. 3:55. doi: 10.3389/fphar.2012.00055
19. Wegiel, B., and Otterbein, L. E. (2012). Go green: the anti-inflammatory effects of biliverdin reductase. Front. Pharmacol. 3:47. doi: 10.3389/fphar.2012.00047